RxDoctor Payments Data

Frank Barber, PA

Physician Assistant · Cooperstown, NYNPI 1609834100

Payments from drug & device makers

$1,788in general payments, 2019–2025

Across 31 payments — averaging $57.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$813
  • Baxter Healthcare$182
  • Neurocrine Biosciences, Inc.$156
  • Lifenet Health$119
  • Next Science LLC$116
  • Orthalign Inc$90
  • plus $312 from 10 others

What the payments were for

  • Travel & lodging$64636%
  • Food & beverage$1,14264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,788 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$140,361
Medicare patients
318
Services billed
2,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate45$176,291
EliquisApixaban347$104,960
XtandiEnzalutamide14$98,741
NuplazidPimavanserin Tartrate27$65,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$51,886
Bydureon BciseExenatide Microspheres37$31,472
TrulicityDulaglutide31$31,419
JardianceEmpagliflozin87$26,867
RexultiBrexpiprazole34$24,159
XareltoRivaroxaban83$24,091
OzempicSemaglutide13$13,411
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog155$12,823
ZenpepLipase/Protease/Amylase13$11,678
Paliperidone ErPaliperidone24$10,940
Mesalamine15$10,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$156$176,29145 claims
Acadia Pharmaceuticals IncNuplazid$44$65,36327 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$24,15934 claims
Johnson & JohnsonXarelto$813$24,09183 claims
Smith+NephewSantyl$29$7,76424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Cooperstown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →